• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » TriReme, founder win AngioScore patent spat, lose bid for legal fees

TriReme, founder win AngioScore patent spat, lose bid for legal fees

December 11, 2015 By Brad Perriello

AngioScore, TriReme Medical, Quattro Vascular, QT Vascular

AngioScore lost the patent infringement portion of its legal war with co-founder and former board member Eitan Konstantino, but won’t have to pay its opponents’ $4.8 million legal tab, a federal judge ruled this week.

AngioScore, which accused Konstantino of violating his fiduciary duties when he started TriReme Medical, Quattro Vascular and QT Vascular, won a $20 million judgment in July that the defendants are appealing. But the patent infringement case, which Judge Yvonne Gonzalez Rogers of the U.S. District Court for Northern California split from the suit in March, went the other way after a jury returned a verdict Sept. 29 of non-infringement and invalidity.

TriReme and its co-defendants in October asked Gonzalez Rogers to order AngioScore to cough up $4.8 million to cover its legal costs. AngioScore’s infringement theories were “exceptionally meritless,” they argued, according to court documents.

Citing an email from AngioScore CEO Tom Trotter, the defendants argued that AngioScore’s intent with the patent infringement case was to disrupt a potential acquisition.

“In fact, in an e-mail sent only weeks before AngioScore filed its complaint for patent infringement, AngioScore’s CEO, Tom Trotter, confirmed that the lawsuit was intended to disrupt investment in or acquisition of Defendants by a company that his subordinate thought might be interested in TriReme: ‘If so, they may be in for a big surprise when they move toward a close and find TriReme is facing a potential major lawsuit,'” they argued, according to the documents. “Mr. Trotter also boasted to AngioScore’s sales team: “They [Defendants] will soon be hearing from us.”

But Gonzalez Rogers found nothing “inherently suspect” in Trotter’s comments.

“A CEO might make such a remark regarding a suit brought in good faith,” she wrote.

“The court finds that the totality of the circumstances at issue here does not suggest the patent suit was brought in bad faith, with an improper purpose, or in the absence of an adequate pre-filing investigation. Defendants have put forth no authority supporting an exceptional case finding in such a context,” Gonzalez Rogers wrote.

Filed Under: Legal News, Patent Infringement Tagged With: AngioScore Inc., QT Vascular, Quattro Vascular, TriReme Medical Inc.

More recent news

  • EBR Systems raises $36.1M for leadless pacing tech
  • The biggest cardiovascular tech news out of EuroPCR 2025
  • CardiaWave has positive 12-month Valvosoft results
  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Medtronic has new Cardiovascular, CST leaders after longtime exec departs

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy